Global MedTech Giants Including Medtronic, Johnson & Johnson, and Abbott Report Strong Q2 2026 Financial Results

Click the blue text above to follow“Medical Device Innovation Network”

Note: The fiscal year start dates for major companies differ from the calendar year, leading to discrepancies between fiscal quarters/years and calendar periods. Companies may release financial performance reports on a quarterly or semi-annual basis.

Medical Devices and Diagnostics

Medtronic Announces First-Quarter Results for the Period Ended July 31, 2026. Quarterly net sales amounted to $9.756 billion, compared to $8.578 billion in the same period last year, representing a year-over-year increase of 13.7%. Quarterly operating profit was $1.764 billion, compared to $1.445 billion in the same period last year. Quarterly net income attributable to the company was $1.47 billion, compared to $1.04 billion in the same period last year.

Johnson & Johnson Announces Second Quarter 2026 Results. Quarterly sales amounted to $25.31 billion, compared to $23.743 billion in the same period last year, representing a year-over-year increase of 6.6%. Among these, Innovative Medicine sales reached $16.384 billion, a year-over-year increase of 7.8%; MedTech sales totaled $8.926 billion, a year-over-year increase of 4.5%. Net income for the quarter was $5.534 billion, compared to $5.537 billion in the same period last year.

Abbott Announces Second Quarter 2026 Results. Net sales for the quarter were $12.593 billion, compared to $11.142 billion in the same period last year, representing a 13% year-over-year increase. Operating profit for the quarter was $1.693 billion, down 17.5% from $2.052 billion in the same period last year. Net income for the quarter was $928 million, a 47.8% decline from $1.779 billion in the same period last year. By segment, Medical Devices sales were $5.853 billion, Diagnostics sales were $3.092 billion, Pharmaceutical sales were $1.499 billion, and Nutrition sales were $2.144 billion.

Medline Announces Second Quarter 2026 Results. Quarterly net sales were $7.685 billion, compared to $6.886 billion in the same period last year, representing a year-over-year increase of 11.6%. Quarterly operating profit was $395 million, down from $642 million in the same period last year, a year-over-year decrease of 38.5%. Quarterly net income attributable to the company was $60 million, compared to $333 million in the same period last year, a year-over-year decrease of 82%.

Siemens Healthineers Announces Third-Quarter Fiscal 2026 Results Ended June 30, 2026. Quarterly revenue reached €5.764 billion (approximately $6.67 billion), compared to €5.662 billion in the same period last year, representing a year-over-year increase of 1.8%. Adjusted quarterly EBIT amounted to €1.101 billion, up from €953 million in the prior-year period, marking a 15.6% year-over-year growth. Quarterly net profit totaled €676 million, compared to €556 million in the same period last year, reflecting a 21.7% year-over-year increase.

Stryker Announces Second Quarter 2026 Financial Results. Quarterly net sales were $6.589 billion, compared to $6.022 billion in the same period last year, representing a year-over-year increase of 9.4%. Quarterly operating profit was $1.659 billion, compared to $1.113 billion in the same period last year, representing a year-over-year increase of 49.1%. Quarterly net income was $1.276 billion, compared to $884 million in the same period last year, representing a year-over-year increase of 44.3%.

Danaher Announces Second Quarter 2026 Results. Quarterly sales were $6.265 billion, compared to $5.936 billion in the same period last year. Quarterly operating profit was $1.127 billion, compared to $760 million in the same period last year. Quarterly net income was $870 million, compared to $555 million in the same period last year.

Fresenius Medical Care, the German leader in dialysis care, announces its second-quarter 2026 financial results. Quarterly revenue amounted to €4.861 billion (approximately $5.63 billion), compared to €4.792 billion in the same period last year. Quarterly operating profit was €466 million, up from €425 million a year earlier. Quarterly net profit stood at €218 million, compared to €225 million in the prior-year period.

Boston Scientific Announces Second Quarter 2026 Results. Quarterly net sales were $5.442 billion, compared to $5.061 billion in the same period last year. Quarterly operating profit was $1.178 billion, compared to $819 million in the same period last year. Quarterly net income attributable to common shareholders was $907 million, compared to $797 million in the same period last year.

GE HealthCare Announces Q2 2026 Financial Results. Total quarterly revenue amounted to $5.295 billion, compared to $5.007 billion in the same period last year. Quarterly operating profit reached $739 million, up from $654 million in the prior-year period. Net income attributable to the company for the quarter was $561 million, compared to $486 million in the same period last year.

Philips Announces Q2 2026 Financial Results. Quarterly sales amounted to €4.36 billion (approximately $5.05 billion), compared to €4.338 billion in the same period last year. Quarterly operating profit reached €609 million, up from €400 million a year earlier. Quarterly net profit stood at €386 million, compared to €240 million in the same period of the previous year.

BD Reports Third Fiscal Quarter Results Ended June 30, 2026. Quarterly revenue was $4.983 billion, compared to $4.726 billion in the same period last year, representing a year-over-year increase of 5.4%. Quarterly operating profit was $663 million, down from $739 million in the same period last year, a year-over-year decrease of 10.3%. Quarterly net income was $377 million, compared to $574 million in the same period last year, a year-over-year decrease of 34.3%.

Roche Announces First-Half 2026 Results. The Group’s sales for the period amounted to CHF 30.364 billion, compared to CHF 30.944 billion in the same period last year, representing a 2% year-on-year decline. IFRS operating profit was CHF 9.671 billion, down 1% from CHF 10.33 billion in the previous year. Net profit attributable to shareholders of the company was CHF 6.871 billion. Specifically, the Pharmaceuticals division reported sales of CHF 23.629 billion, a 1% decrease from CHF 23.985 billion in the same period last year, with an operating profit of CHF 10.838 billion. The Diagnostics division recorded sales of CHF 6.735 billion (approximately USD 8.286 billion), a 3% decline from CHF 6.959 billion in the previous year, with an operating profit of CHF 870 million.

Thermo Fisher Scientific Announces Second Quarter 2026 Results. Quarterly revenue amounted to $11.994 billion, compared to $10.855 billion in the same period last year. Quarterly operating profit was $2.087 billion, compared to $1.834 billion in the same period last year. Net income attributable to the company for the quarter was $1.736 billion, compared to $1.617 billion in the same period last year. Among these, Life Sciences Solutions revenue was $2.815 billion, Laboratory Products and Biopharma Services revenue was $6.693 billion, Specialty Diagnostics revenue was $1.205 billion, and Analytical Instruments revenue was $1.847 billion.

Henry Schein Announces Second Quarter 2026 Results. Quarterly net sales were $3.458 billion, compared to $3.24 billion in the same period last year. Quarterly operating profit was $171 million, compared to $151 million in the same period last year. Quarterly net income attributable to the company was $94 million, compared to $86 million in the same period last year.

Cardinal Health Reports Fourth-Quarter and Fiscal Year Results for the Period Ended June 30, 2026Fourth-quarter revenue reached $63.672 billion, a 6% year-over-year increase. Net income attributable to the company for the quarter was $398 million, representing a 67% year-over-year growth. Of this, the Medical Products and Distribution segment generated $3.1 billion in revenue and $150 million in profit.For the full fiscal year, revenue totaled $254.248 billion, up 14% year over year. Net income attributable to the company for the fiscal year was $1.714 billion, a 10% year-over-year increase. The Medical Products and Distribution segment contributed $12.7 billion in revenue and $258 million in profit.

Baxter International Announces Second Quarter 2026 Results. Quarterly net sales were $2.96 billion, compared to $2.81 billion in the same period last year, representing a 5% year-over-year increase. Quarterly operating profit was $217 million, compared to $191 million in the same period last year, representing a 14% year-over-year increase. Quarterly net income attributable to shareholders was $126 million, compared to $91 million in the same period last year, representing a 38% year-over-year increase.

Intuitive Surgical Announces Second Quarter 2026 Financial Results. Total quarterly revenue was $2.892 billion, compared to $2.44 billion in the same period last year. Quarterly operating profit was $972 million, compared to $855 million in the same period last year. Net income attributable to the company was $818 million for the quarter, compared to $822 million in the same period last year.

Solventum Announces Second Quarter 2026 Financial Results. Quarterly net sales were $2.209 billion, compared to $2.161 billion in the same period last year, representing a year-over-year increase of 2.2%. Quarterly net income was $92 million, compared to $90 million in the same period last year, representing a year-over-year increase of 2.2%.

Zimmer Biomet Holdings Announces Second Quarter 2026 Results. Quarterly net sales were $2.177 billion, compared to $2.077 billion in the same period last year. Quarterly operating profit was $326 million, compared to $300 million in the same period last year. Quarterly net income attributable to the company was $198 million, compared to $153 million in the same period last year.

Terumo Announces First-Quarter Results for the Fiscal Year Ending June 30, 2026. Quarterly revenue reached JPY 311.81 billion (approximately USD 1.96 billion), compared to JPY 259.965 billion in the same period last year, representing a year-on-year increase of 19.9%. Quarterly operating profit amounted to JPY 89.48 billion, up from JPY 55.885 billion in the previous year, a year-on-year increase of 60.1%. Net profit attributable to owners of the parent company for the quarter was JPY 70.426 billion, compared to JPY 41.843 billion in the same period last year, marking a year-on-year increase of 68.3%.

Olympus (OLYMPUS) Announces First Quarter Fiscal 2026 Results for the Period Ended June 30, 2026Quarterly revenue amounted to JPY 240.4 billion (approximately USD 1.51 billion), representing a 16.4% year-on-year increase from JPY 206.512 billion in the same period of the previous year. Quarterly operating profit reached JPY 28.951 billion, a 74.4% year-on-year increase from JPY 16.597 billion in the prior year. Net income attributable to owners of the parent company for the quarter was JPY 19.102 billion, marking a 112.5% year-on-year increase from JPY 8.991 billion in the same period of the previous year.

Fujifilm Holdings Announces First-Quarter Results for the Fiscal Year Ending June 30, 2026Fujifilm Holdings Corporation announced its financial results for the first quarter ended June 30, 2026. Quarterly revenue reached JPY 826.493 billion, compared to JPY 749.482 billion in the same period last year, representing a year-on-year increase of 10.3%. Quarterly operating profit amounted to JPY 51.184 billion, down 32% from JPY 75.291 billion in the previous year. Net income attributable to the company stood at JPY 37.424 billion, a 30.4% decline from JPY 53.767 billion in the same period last year.By business segment, the Healthcare sector generated revenue of JPY 256.8 billion (approximately USD 1.612 billion), a 12.4% year-on-year increase. The Electronic Materials sector reported revenue of JPY 127.7 billion, up 25% year on year. The Imaging sector achieved revenue of JPY 166.8 billion, a 16.2% year-on-year increase. The Business Innovation sector recorded revenue of JPY 273.2 billion, a slight decrease of 0.1% compared to the previous year.

Canon Group Announces First-Half 2026 Financial ResultsCanon Inc. announced its financial results for the first half of 2026. Net sales for the period totaled JPY 2,274.542 billion, representing a 3.5% year-on-year increase from JPY 2,198.567 billion in the same period last year. Operating profit amounted to JPY 230.595 billion, a 7.6% year-on-year increase from JPY 214.308 billion. Net income attributable to the company reached JPY 171.184 billion, up 9.8% year-on-year from JPY 155.904 billion. By business segment, net sales were as follows: Printing Business Unit, JPY 1,239.879 billion; Medical Business Unit, JPY 277.447 billion (approximately USD 1.743 billion); Imaging Business Unit, JPY 552.694 billion; and Industrial Business Unit, JPY 145.227 billion.

Ophthalmology

EssilorLuxottica Reports First-Half 2026 ResultsEyewear giant EssilorLuxottica announced its financial results for the first half of 2026. Revenue for the period reached €14.818 billion, up 5.7% year-over-year from €14.023 billion in the same period last year. Operating profit amounted to €2.751 billion, representing an 8.7% increase from €2.532 billion a year earlier. The Group’s net profit stood at €1.921 billion, a 6.8% rise compared to €1.799 billion in the prior year. In the second quarter, the Group reported revenue of €7.692 billion, compared to €7.175 billion in the same quarter of the previous year. Of this, the Professional Solutions business generated revenue of €3.454 billion (approximately $4 billion), up from €3.329 billion a year earlier. The Consumer Goods business recorded revenue of €4.237 billion, compared to €3.846 billion in the prior year.

Alcon Announces Second Quarter 2026 Results. Quarterly net sales and other revenues totaled $2.823 billion, compared to $2.596 billion in the same period last year. Quarterly operating profit was $11 million, compared to $247 million in the same period last year.

Bausch + Lomb Announces Second Quarter 2026 Financial Results. Quarterly revenue amounted to $1.394 billion, compared to $1.278 billion in the same period last year. Quarterly operating profit was $83 million, compared to an operating loss of $11 million in the same period last year. The net loss attributable to the company for the quarter was $14 million, compared to a net loss of $62 million in the same period last year.

END

▲Source: PharmaHealth News

▲No reproduction without authorization

Disclaimer: This article is intended solely for informational purposes and should be used for reference only. It does not constitute any advice on investment or treatment; please exercise due diligence in your assessment. If there are any issues concerning the content, copyright, or other matters, please contact us to protect the rights and interests of all parties involved, and we will address them promptly. Any platform republishing this article shall bear full responsibility for it; Medical Device Innovation Network assumes no liability for secondary dissemination arising from such republication.